Single Cell Genome Sequencing Market Size, Share & Growth Report, 2033
The global single cell genome sequencing market size was estimated at USD 3.71 billion in 2023 and is projected to hit around USD 16.64 billion by 2033, growing at a CAGR of 16.2% during the forecast period from 2024 to 2033.
Some of the key trends triggering the market growth are the increasing prevalence of chronic diseases like cancer, diabetes, and arthritis; advanced technology and latest collaborations; and rising geriatric population. In addition, companies are placing greater emphasis on product development, further fueling the market's expansion.
The growth of the market is being significantly influenced by the notable technological advancements in single-cell genome sequencing (SCGS). For instance, the collaboration between Bio-Rad Laboratories, Inc. and Illumina, Inc., aimed at developing an innovative workflow for SCGS analysis. The successful outcome of this collaboration led to the launch of a cutting-edge SCGS solution. These advanced platforms not only offer intuitive analysis software solutions but are also cost-effective, making them a promising addition to the market. As an advanced technology, this procedure is widely used in a variety of research such as in neurology, immunology, cancer, and other such diseases and medical streams. Medical institutes are leveraging SCGS to enhance their complex microbial ecosystems and multicellular organism diseases. Considering these significant findings, SCGS is anticipated to emerge as a valuable asset in the healthcare sector in the coming years.
The COVID-19 pandemic has had a positive impact on the market. Since 2020 and continuing even after the initial phase after the pandemic subsided, many research institutions conducted research studies regarding the effects of single cell sequencing on cells from a COVID-19-positive patient, revealing crucial insights about both. These research efforts have resulted in continuous advancements in the market, leading to an exponential growth.
Single Cell Genome Sequencing Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 4.31 Billion |
| Market Size by 2033 | USD 16.64 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 16.2% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Product type, technology, workflow, disease area, application, end-use, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Bio-Rad Laboratories; 10x Genomics; Novogene; Fluidigm; BGI; Illumina, Inc.; Oxford Nanopore Technologies; Pacific Biosciences; Thermo Fisher Scientific, Inc.; QIAGEN; F Hoffmann-La Roche Ltd. |
In terms of product, the instruments segment dominated the market in 2023, with a revenue share of 58.43%. This dominance can be primarily attributed to the accelerated development and adoption of technologically advanced instruments and solutions, specifically designed to keep pace with the dynamic changes in healthcare technological advancements. This segment is expected to witness the fastest CAGR of 16.2% over the forecast period due to the increased focus of market players on developing and manufacturing these instruments. Such efforts aim to expand their market presence and seize opportunities to enter new markets.
In terms of technology, the PCR segment dominated the market in 2023 with a revenue share of 28.77%. Due to heavy investments in R&D, PCR is a widely recognized technology when it comes to genome sequencing, highly coveted by market leaders and research institutes. NGS is poised to emerge as the fastest-growing technology segment with a CAGR of 17.1% over the forecast period. This remarkable growth can be attributed to extensive R&D activities and its diverse applications in cancer-related investigations.
Genome sequencing has evolved significantly over the past few years due to constant technological advancements. For instance, in March 2023, researchers at ETH Zurich used a new approach using single-cell genome sequencing to analyze the DNA from two different T-cells that were obtained from the same period. This sequencing data revealed 28 somatic mutations that differentiated the two T-cells and identified any mitochondrial DNA changes. It was inferred that this new method could potentially allow scientists to study various impacts of somatic mutations in a host of diseases.
The workflow segment is divided into genomic analysis, single cell isolation, and sample preparation. The genomic analysis segment dominated the market in 2023, with a market size of 70.28%. This dominance can be attributed to the recent surge in funding for research and development capabilities and the widespread adoption of genomic analysis products. As a result, this segment is projected to experience the fastest CAGR of 16.9% during the forecast period.
These recent developments have also created new opportunities for mutation rate quantification, rare cell type identification, and other diagnoses and treatments. Genomic analysis allows comprehensive identification, measurement, and comparison of genomic features like DNA sequence, gene expression, and other regulatory and functional annotations. This analysis allows companies to study cells in depth, ensuring lucrative growth for this segment. For instance, a research publication released on 30th May 2023, showcased how genomic analysis studies have revealed candidate genes associated with milk production and adaptive traits in goat breeds. These findings exemplify the potential and significance of genomic analysis in uncovering valuable insights in diverse fields of research.
The disease area segment is divided into cancer, immunology, prenatal diagnosis, neurobiology, microbiology, and others. The cancer segment dominated the market in 2023 with a revenue share of 35.75%. The increasing prevalence of prostate, colorectal, and breast cancer is projected to generate lucrative opportunities for market growth. Notably, according to the American Cancer Society, cancer ranks as the second leading cause of mortality in the U.S.
With an increase in cancer incidences, there has been a complementary increase in the number of research studies and experiments being conducted. Therefore, rise in cancer incidences is also causing a growth in the SCGS market. For instance, in October 2022, researchers from UBC and the BC Cancer Research Institute conducted cancer-related research, which showed that single cell genome sequencing provided new insights into deadly cancers. The researchers were able to sequence the genomes of individual cells from the biopsies of 158 BC Cancer patients, allowing them to observe the processes of evolution within each individual cell.
The application segment is divided into circulating cells, cell differentiation/reprogramming, genomic variation, subpopulation characterization, and others. The circulating cells segment dominated the market in 2023, with a revenue share of 29.45%. This is due to an increase in clinical application of circulating tumor cells (CTCs) as biomarkers for cancer detection, used as genomic profilers for sequence mutations and other such applications.
CTCs allow blood circulation within the primary tumor and regulate tumor metastasis to fight cancer. Due to increasing R&D opportunities and growing number of research, studies, and clinical trials, the circulating cells segment is forecasted to grow at a significant CAGR of 16.3% over the coming years. For instance, in January 2023, researchers at IIT Delhi worked in collaboration with Fluidigm Corporation, US, to develop an innovative and deep dictionary learning to detect circulating cells in the bloodstream, called unCTC.
The prenatal diagnosis segment is anticipated to grow at the fastest CAGR of 17.1% over the forecast period owing to the increasing number of medical tests and procedures that are performed during pregnancy to detect potential health issues or abnormalities in the developing fetus coupled with higher resolution and accuracy of SCGS compared to traditional sequencing methods.
The end-use segment is divided into academic & research laboratories, biotechnology & biopharmaceutical companies, clinics, and others. The academic & research laboratories segment dominated the market in 2023, with a revenue share of 73%. This growth is attributed to the rise in genomic centers, increase in life science research funding, and growing number of medical colleges and institutions in major regions.
The biotechnology & biopharmaceutical companies segment is anticipated to grow at the fastest CAGR over the forecast period. This is due to the increasing dependency of medical institutions and hospitals on these companies for research access, results, and other equipment and related contingencies. Due to their strong market presence and desire to enter the single-cell genome sequencing market, many biotechnology companies are pursuing different competitive strategies to stretch their lead. As a result, this segment is anticipated to grow significantly.
North America dominated the regional market in 2023, with a revenue share of 48%. This dominance can be attributed to several factors, including the increasing incidence of cancer and other chronic diseases in the region. In addition, the continuous advancements in technology and research and development efforts by companies in North America have contributed to this lead. Moreover, the rise in the number of genomic clinics in the region has further boosted its position in the market.
Asia Pacific is anticipated to grow at the fastest CAGR of 17.5% over the forecast period. One of the primary drivers of the growth is the rising geriatric population, leading to an increased prevalence of chronic diseases among patients. In addition, the region is anticipated to witness significant advancements in healthcare infrastructure, driven by developing countries' efforts to boost their economies.
Major companies are continually striving for progress to establish themselves as market leaders. Consequently, the market is witnessing numerous activities such as acquisitions, product launches, and the implementation of competitive strategies. Moreover, companies are actively expanding their research and development initiatives while introducing cutting-edge technological advancements in the industry.
For instance, in October 2022, Oxford Nanopore Technologies PLC announced a collaboration with 10x Genomics, aimed at streamlining the workflow to enable the sequencing of full length transcripts in single reads on Oxford Nanopore devices. This collaboration will facilitate single cell sequencing accessible to any laboratory, thereby increasing efficiency and cost reduction benefits. Some prominent players in the global single cell genome sequencing market include:
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Single Cell Genome Sequencing market.
By Product Type
By Technology
By Workflow
By Disease Area
By Application
By End-use
By Region
Chapter 1. Single Cell Genome Sequencing Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment definitions
1.1.1.1. Product segment
1.1.1.2. Workflow segment
1.1.1.3. Application segment
1.1.1.4. Technology segment
1.1.1.5. Disease Area segment
1.1.1.6. End-use segment
1.1.2. Regional Scope
1.1.3. Estimates and forecast time.
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. nova one advisor internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information Or Data Analysis
1.4.1. Data analysis models
1.5. Market formulation and validation
1.6. Objectives
1.6.1. Objective 1
1.6.2. Objective 2
1.6.3. Objective 3
Chapter 2. Single Cell Genome Sequencing Market: Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Single Cell Genome Sequencing Market: Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Product Launches by Market Players
3.2.1.2. Increasing Prevalence of Cancer
3.2.1.3. High R&D in the Single Cell Genomics Space
3.2.2. Market Restraint Analysis
3.2.2.1. High Costs of Genome Sequencing Instruments
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Product Type Business Analysis
4.1. Single Cell Genome Sequencing Market: Product Type Movement Analysis
4.2. Instruments
4.2.1. Instruments Market, 2021 - 2033
4.3. Reagents
4.3.1. Reagents Market, 2021 - 2033
Chapter 5. Technology Business Analysis
5.1. Single Cell Genome Sequencing Market: Technology Movement Analysis
5.2. NGS
5.2.1. NGS Market, 2021 - 2033
5.3. PCR
5.3.1. PCR Market, 2021 - 2033
5.4. qPCR
5.4.1. qPCR Market, 2021 - 2033
5.5. Microarray
5.5.1. Microarray Market, 2021 - 2033
5.6. MDA
5.6.1. MDA Market, 2021 - 2033
Chapter 6. Workflow Business Analysis
6.1. Single Cell Genome Sequencing Market: Workflow Movement Analysis
6.2. Genomic Analysis
6.2.1. Genomic Analysis Market, 2021 - 2033
6.3. Single Cell Isolation
6.3.1. Single Cell Isolation Market, 2021 - 2033
6.4. Sample Preparation
6.4.1. Sample Preparation Market, 2021 - 2033
Chapter 7. Disease Area Business Analysis
7.1. Single Cell Genome Sequencing Market: Disease Area Movement Analysis
7.2. Cancer
7.2.1. Cancer Market, 2021 - 2033
7.3. Immunology
7.3.1. Immunology Market, 2021 - 2033
7.4. Prenatal Diagnosis
7.4.1. Prenatal Diagnosis Market, 2021 - 2033
7.5. Neurobiology
7.5.1. Neurobiology Market, 2021 - 2033
7.6. Microbiology
7.6.1. Microbiology Market, 2021 - 2033
7.7. Others
7.7.1. Other Disease Areas Market, 2021 - 2033
Chapter 8. Application Business Analysis
8.1. Single Cell Genome Sequencing Market: Application Movement Analysis
8.2. Circulating Cells
8.2.1. Circulating Cells Market, 2021 - 2033
8.3. Cell Differentiation/Reprogramming
8.3.1. Cell Differentiation/Reprogramming Market, 2021 - 2033
8.4. Genomic Variation
8.4.1. Genomic Variation Market, 2021 - 2033
8.5. Subpopulation Characterization
8.5.1. Subpopulation Characterization Market, 2021 - 2033
8.6. Others
8.6.1. Other Applications Market, 2021 - 2033
Chapter 9. End-use Business Analysis
9.1. Single Cell Genome Sequencing Market: End-use Movement Analysis
9.2. Academic & Research Laboratories
9.2.1. Academic & Research Laboratories Market, 2021 - 2033
9.3. Biotechnology & Biopharmaceutical Companies
9.3.1. Biotechnology & Biopharmaceutical Companies Market, 2021 - 2033
9.4. Clinics
9.4.1. Clinics Market, 2021 - 2033
9.5. Others
9.5.1. Other End-uses Market, 2021 - 2033
Chapter 10. Regional Business Analysis
10.1. Single Cell Genome Sequencing Market Share, By Region, 2024 & 2033
10.2. North America
10.2.1. SWOT Analysis
10.2.2. North America Single Cell Genome Sequencing Market, 2021 - 2033
10.2.3. U.S.
10.2.3.1. Key Country Dynamics
10.2.3.2. Target Disease Prevalence
10.2.3.3. Competitive Scenario
10.2.3.4. Regulatory Framework
10.2.3.5. U.S. Single Cell Genome Sequencing Market, 2021 - 2033
10.2.4. Canada
10.2.4.1. Key Country Dynamics
10.2.4.2. Target Disease Prevalence
10.2.4.3. Competitive Scenario
10.2.4.4. Regulatory Framework
10.2.4.5. Canada Single Cell Genome Sequencing Market, 2021 - 2033
10.3. Europe
10.3.1. SWOT Analysis
10.3.2. Europe Single Cell Genome Sequencing Market, 2021 - 2033
10.3.3. UK
10.3.3.1. Key Country Dynamics
10.3.3.2. Target Disease Prevalence
10.3.3.3. Competitive Scenario
10.3.3.4. Regulatory Framework
10.3.3.5. UK Single Cell Genome Sequencing Market, 2021 - 2033
10.3.4. Germany
10.3.4.1. Key Country Dynamics
10.3.4.2. Target Disease Prevalence
10.3.4.3. Competitive Scenario
10.3.4.4. Regulatory Framework
10.3.4.5. Germany Single Cell Genome Sequencing Market, 2021 - 2033
10.3.5. France
10.3.5.1. Key Country Dynamics
10.3.5.2. Target Disease Prevalence
10.3.5.3. Competitive Scenario
10.3.5.4. Regulatory Framework
10.3.5.5. France Single Cell Genome Sequencing Market, 2021 - 2033
10.3.6. Italy
10.3.6.1. Key Country Dynamics
10.3.6.2. Target Disease Prevalence
10.3.6.3. Competitive Scenario
10.3.6.4. Regulatory Framework
10.3.6.5. Italy Single Cell Genome Sequencing Market, 2021 - 2033
10.3.7. Spain
10.3.7.1. Key Country Dynamics
10.3.7.2. Target Disease Prevalence
10.3.7.3. Competitive Scenario
10.3.7.4. Regulatory Framework
10.3.7.5. Spain Single Cell Genome Sequencing Market, 2021 - 2033
10.3.8. Denmark
10.3.8.1. Key Country Dynamics
10.3.8.2. Target Disease Prevalence
10.3.8.3. Competitive Scenario
10.3.8.4. Regulatory Framework
10.3.8.5. Denmark Single Cell Genome Sequencing Market, 2021 - 2033
10.3.9. Sweden
10.3.9.1. Key Country Dynamics
10.3.9.2. Target Disease Prevalence
10.3.9.3. Competitive Scenario
10.3.9.4. Regulatory Framework
10.3.9.5. Sweden Single Cell Genome Sequencing Market, 2021 - 2033
10.3.10. Norway
10.3.10.1. Key Country Dynamics
10.3.10.2. Target Disease Prevalence
10.3.10.3. Competitive Scenario
10.3.10.4. Regulatory Framework
10.3.10.5. Norway Single Cell Genome Sequencing Market, 2021 - 2033
10.4. Asia Pacific
10.4.1. SWOT Analysis
10.4.2. Asia Pacific Single Cell Genome Sequencing Market, 2021 - 2033
10.4.3. Japan
10.4.3.1. Key Country Dynamics
10.4.3.2. Target Disease Prevalence
10.4.3.3. Competitive Scenario
10.4.3.4. Regulatory Framework
10.4.3.5. Japan Single Cell Genome Sequencing Market, 2021 - 2033
10.4.4. China
10.4.4.1. Key Country Dynamics
10.4.4.2. Target Disease Prevalence
10.4.4.3. Competitive Scenario
10.4.4.4. Regulatory Framework
10.4.4.5. China Single Cell Genome Sequencing Market, 2021 - 2033
10.4.5. India
10.4.5.1. Key Country Dynamics
10.4.5.2. Target Disease Prevalence
10.4.5.3. Competitive Scenario
10.4.5.4. Regulatory Framework
10.4.5.5. India Single Cell Genome Sequencing Market, 2021 - 2033
10.4.6. Australia
10.4.6.1. Key Country Dynamics
10.4.6.2. Target Disease Prevalence
10.4.6.3. Competitive Scenario
10.4.6.4. Regulatory Framework
10.4.6.5. Australia Single Cell Genome Sequencing Market, 2021 - 2033
10.4.7. Thailand
10.4.7.1. Key Country Dynamics
10.4.7.2. Target Disease Prevalence
10.4.7.3. Competitive Scenario
10.4.7.4. Regulatory Framework
10.4.7.5. Thailand Single Cell Genome Sequencing Market, 2021 - 2033
10.4.8. South Korea
10.4.8.1. Key Country Dynamics
10.4.8.2. Target Disease Prevalence
10.4.8.3. Competitive Scenario
10.4.8.4. Regulatory Framework
10.4.8.5. South Korea Single Cell Genome Sequencing Market, 2021 - 2033
10.5. Latin America
10.5.1. SWOT Analysis
10.5.2. Latin America Single Cell Genome Sequencing Market, 2021 - 2033
10.5.3. Brazil
10.5.3.1. Key Country Dynamics
10.5.3.2. Target Disease Prevalence
10.5.3.3. Competitive Scenario
10.5.3.4. Regulatory Framework
10.5.3.5. Brazil Single Cell Genome Sequencing Market, 2021 - 2033
10.5.4. Mexico
10.5.4.1. Key Country Dynamics
10.5.4.2. Target Disease Prevalence
10.5.4.3. Competitive Scenario
10.5.4.4. Regulatory Framework
10.5.4.5. Mexico Single Cell Genome Sequencing Market, 2021 - 2033
10.5.5. Argentina
10.5.5.1. Key Country Dynamics
10.5.5.2. Target Disease Prevalence
10.5.5.3. Competitive Scenario
10.5.5.4. Regulatory Framework
10.5.5.5. Argentina Single Cell Genome Sequencing Market, 2021 - 2033
10.6. MEA
10.6.1. SWOT Analysis
10.6.2. MEA Single Cell Genome Sequencing Market, 2021 - 2033
10.6.3. South Africa
10.6.3.1. Key Country Dynamics
10.6.3.2. Target Disease Prevalence
10.6.3.3. Competitive Scenario
10.6.3.4. Regulatory Framework
10.6.3.5. South Africa Single Cell Genome Sequencing Market, 2021 - 2033
10.6.4. Saudi Arabia
10.6.4.1. Key Country Dynamics
10.6.4.2. Target Disease Prevalence
10.6.4.3. Competitive Scenario
10.6.4.4. Regulatory Framework
10.6.4.5. Saudi Arabia Single Cell Genome Sequencing Market, 2021 - 2033
10.6.5. UAE
10.6.5.1. Key Country Dynamics
10.6.5.2. Target Disease Prevalence
10.6.5.3. Competitive Scenario
10.6.5.4. Regulatory Framework
10.6.5.5. UAE Single Cell Genome Sequencing Market, 2021 - 2033
10.6.6. Kuwait
10.6.6.1. Key Country Dynamics
10.6.6.2. Target Disease Prevalence
10.6.6.3. Competitive Scenario
10.6.6.4. Regulatory Framework
10.6.6.5. Kuwait Single Cell Genome Sequencing Market, 2021 - 2033
Chapter 11. Competitive Landscape
11.1. Company Categorization
11.2. Strategy Mapping
11.3. Company Market Share Analysis, 2022
11.4. Company Profiles/Listing
11.4.1. Bio-Rad Laboratories
11.4.1.1. Overview
11.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.1.3. Product Benchmarking
11.4.1.4. Strategic Initiatives
11.4.2. 10x Genomics
11.4.2.1. Overview
11.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.2.3. Product Benchmarking
11.4.2.4. Strategic Initiatives
11.4.3. Novogene Co, Ltd
11.4.3.1. Overview
11.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.3.3. Product Benchmarking
11.4.3.4. Strategic Initiatives
11.4.4. Fluidigm
11.4.4.1. Overview
11.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.4.3. Product Benchmarking
11.4.4.4. Strategic Initiatives
11.4.5. BGI
11.4.5.1. Overview
11.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.5.3. Product Benchmarking
11.4.5.4. Strategic Initiatives
11.4.6. Illumina, Inc.
11.4.6.1. Overview
11.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.6.3. Product Benchmarking
11.4.6.4. Strategic Initiatives
11.4.7. Oxford Nanopore Technologies plc.
11.4.7.1. Overview
11.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.7.3. Product Benchmarking
11.4.7.4. Strategic Initiatives
11.4.8. Pacific Biosciences
11.4.8.1. Overview
11.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.8.3. Product Benchmarking
11.4.8.4. Strategic Initiatives
11.4.9. Thermo Fisher Scientific, Inc.
11.4.9.1. Overview
11.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.9.3. Product Benchmarking
11.4.9.4. Strategic Initiatives
11.4.10. QIAGEN
11.4.10.1. Overview
11.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.10.3. Product Benchmarking
11.4.10.4. Strategic Initiatives
11.4.11. F. Hoffmann La-Roche Ltd.
11.4.11.1. Overview
11.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.11.3. Product Benchmarking
11.4.11.4. Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers